Thomas L Richie Selected Research

HLA-DQ6 antigen

1/2014

HLA class II (DR0401) molecules induce Foxp3+ regulatory T cell suppression of B cells in Plasmodium yoelii strain 17XNL malaria.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas L Richie Research Topics

Disease

84	Malaria 03/2022 - 01/2002
44	Infections 03/2022 - 08/2003
13	Parasitemia 02/2022 - 10/2007
10	Bites and Stings (Sting) 01/2021 - 08/2012
7	Falciparum Malaria (Plasmodium falciparum Malaria) 04/2019 - 03/2002
4	Communicable Diseases (Infectious Diseases) 01/2020 - 02/2002
2	Tuberculosis (Tuberculoses) 12/2017 - 08/2013
2	Fever (Fevers) 01/2017 - 07/2003
2	Vivax Malaria 02/2016 - 04/2006
2	Parasitic Diseases (Parasitic Disease) 12/2015 - 11/2015
1	Lymphadenopathy 11/2020
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 11/2020
1	Sickle Cell Trait 01/2018
1	Headache (Headaches) 01/2017
1	Fatigue 01/2017
1	Myalgia 01/2017
1	Body Weight (Weight, Body) 04/2010
1	Neoplasms (Cancer) 05/2004
1	Acquired Immunodeficiency Syndrome (AIDS) 05/2004
1	Pruritus (Itching) 07/2003
1	Tinnitus 07/2003
1	Heartburn (Pyrosis) 07/2003
1	Exanthema (Rash) 07/2003
1	Hearing Loss (Hearing Impairment) 07/2003
1	Paresthesia (Dysesthesia) 07/2003

Drug/Important Bio-Agent (IBA)

66	VaccinesIBA 02/2022 - 01/2002
26	1- acetyl- 1,2,3,3a,8,8a- hexahydro- 8a- hydroxy- 5- methoxypyrrolo(2,3- b)indole (CHMI)IBA 03/2022 - 08/2012
19	AntigensIBA 02/2022 - 06/2004
19	Malaria VaccinesIBA 01/2022 - 02/2007
11	Proteins (Proteins, Gene)FDA Link 02/2022 - 08/2003
11	AntibodiesIBA 02/2022 - 08/2003
10	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 03/2002
5	EpitopesIBA 01/2021 - 06/2004
5	Chloroquine (Aralen)FDA LinkGeneric 01/2021 - 04/2006
5	DNA VaccinesIBA 11/2012 - 03/2002
4	Antimalarials (Antimalarial Agents)IBA 01/2021 - 02/2011
3	Merozoite Surface Protein 1 (MSA1)IBA 02/2022 - 10/2008
3	Peptides (Polypeptides)IBA 01/2021 - 08/2003
3	Indicators and Reagents (Reagents)IBA 01/2021 - 11/2013
3	A-Form DNA (A-DNA)IBA 01/2021 - 01/2013
3	Pharmaceutical PreparationsIBA 10/2020 - 06/2010
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 11/2009
2	Subunit VaccinesIBA 01/2020 - 01/2013
2	Mefloquine (Lariam)FDA LinkGeneric 01/2017 - 04/2006
2	vaxfectinIBA 04/2010 - 03/2006
2	LipidsIBA 04/2010 - 03/2006
2	ImmunosorbentsIBA 10/2009 - 10/2008
2	EnzymesIBA 10/2009 - 10/2008
2	Doxycycline (Periostat)FDA LinkGeneric 12/2008 - 07/2003
2	Interferon-gamma (Interferon, gamma)IBA 10/2007 - 05/2005
2	Immunoglobulin G (IgG)IBA 06/2004 - 08/2003
2	Recombinant ProteinsIBA 05/2004 - 04/2004
1	Ribosomal DNA (rDNA)IBA 03/2022
1	ThrombospondinsIBA 01/2021
1	Interleukin-2 (IL2)IBA 01/2021
1	Pyrimethamine (Daraprim)FDA Link 01/2021
1	18S Ribosomal RNAIBA 01/2019
1	N-acetyltalosaminuronic acid (NAT)IBA 01/2019
1	Hemoglobins (Hemoglobin)IBA 01/2018
1	Complement System Proteins (Complement)IBA 01/2018
1	Adenovirus VaccinesIBA 01/2017
1	HLA-DR4 Antigen (HLA DR4 Antigen)IBA 01/2014
1	Histocompatibility Antigens Class IIIBA 01/2014
1	HLA-DQ8 antigenIBA 01/2014
1	HLA-DQ6 antigenIBA 01/2014
1	HLA-DR3 Antigen (HLA DR3 Antigen)IBA 01/2014
1	HLA-DR Antigens (HLA-DR)IBA 10/2013
1	AIDS VaccinesIBA 08/2013
1	Galactosylceramides (Galactocerebrosides)IBA 01/2013
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 11/2012
1	Synthetic Vaccines (Recombinant Vaccines)IBA 01/2010
1	Surface Antigens (Surface Antigen)IBA 02/2007
1	Glycosylphosphatidylinositols (Glycosyl-Phosphatidylinositol)IBA 07/2003
1	Azithromycin (Zithromax)FDA LinkGeneric 07/2003

Therapy/Procedure

5	Chemoprevention 01/2021 - 10/2013
3	Injections 01/2021 - 10/2007
2	Mass Drug Administration 01/2017 - 12/2015
1	Intravenous Injections 01/2017
1	Jet Injections 11/2012